In June 1989, FDA-approved Epoetin Alfa was launched in the U.S. in the trade name of “Epogen”. It is sold in over 40 countries nowadays.
According to the research, in 2017, the sales value of Epoetin Alfa was about CNY 546 million in China. Domestic enterprises captured over 90% market share, which formed a market pattern dominated by domestic EPO. CRI's market research shows that, in recent years, Shenyang Sunshine Pharmaceutical Co., Ltd.'s EPIAO takes up more than half of the Chinese Epoetin Alfa market. Other major market players include Shenzhen SCIPROGEN Bio-pharmaceutical Co., Ltd., Shandong Kexing Bioproducts Co., Ltd. and Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd.
EPO is no longer as expensive as it was 10 years ago as manufacturing techniques improve, costs decline and Chinese residents' affordability increases. More than 10% of Chinese adults suffer from chronic kidney disease. The total number of chronic kidney disease patients has exceeded 140 million, and the incidence is still rising. If 1% of the patients eventually get the end-stage renal disease, there will be over 1 million dialysis patients in China. In theory, if a kidney dialysis patient uses 1 ampoule of EPO every 3 days, the annual consumption of EPO injections in Chinese hospitals will be at least 100 million ampoules. However, many patients give up using EPO to alleviate anemia because they cannot afford EPO with their humble income.
In China, the application of EPO in chemotherapy is far below a reasonable level, for tumor patients spend most of their money on antitumor surgeries and drugs. As an adjuvant drug, EPO won't be accepted until antitumor surgeries and drugs are paid up. Therefore, the EPO market inevitably grows more slowly than the antitumor drug market.
The market size of Epoetin Alfa will continue to grow in China from 2018 to 2022 with the economic development and the increase in residents' income.
Topics Covered:
- Development environment of Epoetin Alfa in China
- Demand for Epoetin Alfa in China
- Major Epoetin Alfa Manufacturers in China
- Prices of Epoetin Alfa in China
- Prospects of Chinese Epoetin Alfa Market
Table of Contents
Companies Mentioned
- Beijing Sihuan Biopharmaceutical Co., Ltd.
- Chengdu DIAO Jiuhong Pharmaceutical Factory
- Harbin Pharmaceutical Group Bio-Engineering Co., Ltd.
- Kirin Brewery
- Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.
- NCPC Genetech Biotechnology Co., Ltd.
- Shandong Kexing Bioproducts Co., Ltd.
- Shanghai Chemo Wanbang Biopharmaceutical Co., Ltd.
- Shenyang Sunshine Pharmaceutical Co., Ltd.
- Shenzhen SCIPROGEN Bio-pharmaceutical Co., Ltd.
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
